Olmesartan TecniGen 20 mg film-coated tablets EFG
Spain
Table of Contents
- Package leaflet: Information for the user
- Introduction
- 1. What Olmesartán Tecnigen is and what it is used for
- 2. What you need to know before taking Olmesartán Tecnigen
- 3. How to take Olmesartán Tecnigen
- 4. Possible adverse effects
- 5. Storage of Olmesartán Tecnigen
- 6. Contents of the container and additional information
Package leaflet: Information for the user
Introduction
Package leaflet: information for the user
Olmesartán Tecnigen 20 mg film-coated tablets EFG
Olmesartan medoxomil
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Contents of the leaflet
- What Olmesartán Tecnigen is and what it is used for
- What you need to know before taking Olmesartán Tecnigen
- How to take Olmesartán Tecnigen
- Possible side effects
- How to store Olmesartán Tecnigen
- Contents of the pack and other information
1. What Olmesartán Tecnigen is and what it is used for
Olmesartán Tecnigen belongs to a group of medicines known as angiotensin II receptor antagonists. It lowers blood pressure by relaxing blood vessels.
Olmesartán Tecnigen is used to treat high blood pressure (also known as hypertension). High blood pressure can damage blood vessels in organs such as the heart, kidneys, brain, and eyes. In some cases, this may lead to heart attack, heart or kidney failure, stroke, or blindness. High blood pressure usually does not cause symptoms. It is important to control your blood pressure to prevent organ damage.
High blood pressure can be managed with medications such as Olmesartán Tecnigen tablets. Your doctor has likely also advised you to make certain lifestyle changes to help lower your blood pressure (for example, losing weight, quitting smoking, reducing alcohol consumption, and decreasing the amount of salt in your diet). Your doctor may also recommend that you exercise regularly, such as walking or swimming. It is important to follow your doctor's advice.
2. What you need to know before taking Olmesartán Tecnigen
Do not take Olmesartán Tecnigen
- If you are allergic to olmesartán medoxomilo or to any of the other components of this medicine (listed in section 6).
- If you are more than 3 months pregnant. (It is also advisable to avoid Olmesartán Tecnigen tablets at the beginning of pregnancy – see Pregnancy section).
- If you have yellowing of the skin and eyes (jaundice), or problems with bile drainage from the gallbladder (biliary obstruction, for example due to gallstones).
- If you have diabetes or kidney failure and are being treated with a blood pressure-lowering medicine containing aliskiren.
Warnings and precautions
Talk to your doctor before starting to take Olmesartán Tecnigen.
Tell your doctor if you are taking any of the following medicines used to treat high blood pressure (hypertension):
- An angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g. enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.
- Aliskiren.
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartán Tecnigen”.
Tell your doctor if you have any of the following health conditions:
- Kidney problems.
- Liver disease.
- Heart failure or problems with heart valves or heart muscle.
- Severe vomiting, diarrhoea, treatment with high doses of medicines that increase urine elimination (diuretics), or if you are on a low-salt diet.
- High levels of potassium in the blood.
- Problems with the adrenal glands.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhoea after taking olmesartán. Your doctor will decide whether to continue treatment. Do not stop taking olmesartán used as monotherapy.
Contact your doctor if you develop severe, persistent diarrhoea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
As with any other medicine that lowers blood pressure, excessive lowering of blood pressure in patients with impaired blood flow to the heart or brain may lead to heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
You must inform your doctor if you are pregnant or think you might be pregnant. Use of Olmesartán Tecnigen is not recommended at the beginning of pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this stage (see Pregnancy section).
Children and adolescents
Olmesartán Tecnigen is not recommended for children and adolescents under 18 years of age.
Taking Olmesartán Tecnigen with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any of the following medicines:
- Other blood pressure-lowering medicines, as they may enhance the effect of Olmesartán Tecnigen.
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also information under the headings “Do not take Olmesartán Tecnigen” and “Warnings and precautions”).
- Potassium supplements, salt substitutes containing potassium, medicines that increase urine elimination (diuretics), or heparin (a blood thinner). Using these medicines together with olmesartán may increase potassium levels in the blood.
- Lithium (a medicine used to treat mood disorders and certain types of depression), as it may increase lithium toxicity when taken together with olmesartán. If you need to take lithium, your doctor will monitor lithium blood levels.
- Non-steroidal anti-inflammatory drugs (NSAIDs) (medicines to relieve pain, swelling, and other symptoms of inflammation, including arthritis), as their use together with olmesartán may increase the risk of kidney failure and reduce the effect of Olmesartán Tecnigen.
- Colesevelam hydrochloride, a medicine that lowers blood cholesterol levels, as it may reduce the effect of Olmesartán Tecnigen. Your doctor may advise you to take olmesartán at least 4 hours before colesevelam hydrochloride.
- Certain antacids (remedies for indigestion), as they may slightly reduce the effect of olmesartán.
Elderly patients
If you are over 65 years old and your doctor decides to increase your dose of olmesartán medoxomilo to 40 mg daily, your doctor will regularly monitor your blood pressure to ensure it does not drop too much.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Olmesartán Tecnigen is somewhat reduced in black patients.
Taking Olmesartán Tecnigen with food and drink
Olmesartán Tecnigen may be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant or think you might be pregnant. Your doctor will advise you to stop taking Olmesartán Tecnigen before becoming pregnant or as soon as you know you are pregnant, and will recommend an alternative medicine instead of Olmesartán Tecnigen. Use of olmesartán is not recommended at the beginning of pregnancy, and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if used from the third month of pregnancy onwards.
Breastfeeding
Inform your doctor if you are breastfeeding or about to start breastfeeding. Olmesartán Tecnigen is not recommended for breastfeeding mothers, and your doctor may choose an alternative treatment if you wish to breastfeed, especially if your baby is a newborn or premature.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
You may feel drowsy or dizzy during antihypertensive treatment. If this occurs, do not drive or operate machinery until symptoms have resolved. Consult your doctor.
Olmesartán Tecnigen contains lactose
This medicine contains lactose. If your doctor has diagnosed you with an intolerance to certain sugars, consult him before taking this medicine.
3. How to take Olmesartán Tecnigen
Follow exactly the instructions for using this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended starting dose is 1 tablet of Olmesartán Tecnigen 10 mg once daily. If blood pressure is not adequately controlled, your doctor may increase the dose to 20 mg or 40 mg per day or prescribe additional treatment.
In patients with mild to moderate renal impairment, the maximum dose is 20 mg once daily.
The tablets can be taken with or without food. Take the tablets with a sufficient amount of water (for example, a glass). If possible, take your dose at the same time each day, for example, at breakfast time.
If you take more Olmesartán Tecnigen than you should
If you take more tablets than prescribed or if a child has accidentally ingested the tablets, contact your doctor or the nearest hospital emergency department immediately and bring the medicine packaging with you.
In case of overdose or accidental ingestion, contact the Toxicology Information Service. Telephone 91 562 04 20.
If you forget to take Olmesartán Tecnigen
If you forget to take a dose, take your usual dose the next day. Do not take a double dose to make up for missed doses.
If you stop taking Olmesartán Tecnigen
It is important to continue taking Olmesartán Tecnigen unless your doctor tells you to stop.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine may cause adverse effects, although not everyone experiences them. If they do occur, they are often mild and do not require discontinuation of treatment.
The following adverse effects may be serious, although they affect only a small number of people.
Rare cases (may affect up to 1 in 1,000 people) of the following systemic allergic reactions have been reported: swelling of the face, mouth and/or larynx, together with itching and skin rash. If this happens to you, stop taking Olmesartán Tecnigen and consult your doctor immediately.
Rarely (but slightly more frequently in elderly patients), olmesartan may cause a marked drop in blood pressure in susceptible patients or as a result of an allergic reaction. This may lead to fainting or severe dizziness. If this happens, stop taking Olmesartán Tecnigen, consult your doctor immediately, and remain lying down in a horizontal position.
Frequency not known (cannot be estimated from available data): If you experience yellowing of the whites of the eyes, dark urine, or skin itching—even if you started treatment with olmesartan some time ago—contact your doctor immediately, who will assess your symptoms and decide how to proceed with your blood pressure treatment.
The following are other known adverse effects reported so far with Olmesartán Tecnigen:
Frequent adverse effects (may affect up to 1 in 10 people):
Dizziness, headache, nausea, indigestion, diarrhoea, stomach pain, gastroenteritis, fatigue, sore throat, nasal congestion and discharge, bronchitis, influenza-like symptoms, cough, pain, chest pain, back pain, bone pain, joint pain, urinary tract infection, swelling of ankles, feet, legs, hands, arms, blood in urine.
Some changes in certain blood test results have also been observed:
increase in fat levels (hypertriglyceridaemia), increase in uric acid levels (hyperuricaemia), increase in blood urea, increases in liver and muscle function test values.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid allergic reactions that may affect the whole body and may cause breathing difficulties, as well as a rapid drop in blood pressure that may even lead to fainting (anaphylactic reactions), vertigo, vomiting, weakness, malaise, muscle pain, skin rash, allergic skin rash, itching, exanthema (skin eruption), skin swelling (urticaria), angina pectoris (chest pain or discomfort).
In blood tests, a decrease in the number of a type of blood cells called platelets (thrombocytopenia) has been observed.
Rare adverse effects (may affect up to 1 in 1,000 people):
Lack of energy, muscle cramps, worsening of kidney function, kidney failure.
Some changes in certain blood test results have been observed. These include increased levels of potassium in blood (hyperkalaemia) and increased levels of components related to kidney function.
Intestinal angioedema: swelling in the intestine presenting symptoms such as abdominal pain, nausea, vomiting, and diarrhoea.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if they are effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicinal Products: www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Olmesartán Tecnigen
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging and blister (after "EXP"). The expiry date refers to the last day of the month indicated.
No special storage conditions are required.
Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their packaging at the SIGRE point in your pharmacy. If you have any doubts, ask your pharmacist how to dispose of unused medicines and their packaging. This will help protect the environment.
6. Contents of the container and additional information
Composition of Olmesartán Tecnigen
The active substance is olmesartan medoxomil.
Each film-coated tablet contains 20 mg of olmesartan medoxomil.
The other components are monohydrate lactose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, microcrystalline cellulose, and magnesium stearate.
The coating consists of hypromellose, titanium dioxide (E171), monohydrate lactose, macrogol 3350, and triacetin.
Appearance of the product and contents of the container
Olmesartán Tecnigen 20 mg are film-coated tablets, white, round and biconvex, with the imprint OL20 on one side.
This medicine is available in packs of 28 tablets.
Marketing Authorization Holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D. Edificio América. Polígono Arroyo de la Vega,
28108 Alcobendas (Madrid)
Spain
Manufacturer
Actavis Ltd.,
BLB 016 Bulebel Industrial Estate,
Zejtun ZTN 3000,
Malta
Date of the most recent revision of this leaflet: February 2025
Other sources of information
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/